Abstract
Background Childhood cancer and its treatment may lead to many acute and chronic health complications. Related impairment in quality of life, excess in deaths, and accumulated health care costs are relevant. There is a wide inter-individual variability in the type and severity of health complications. Genetic variations are suggested to contribute to individual susceptibility. So far, only few genetic variants have been used to risk-stratify treatment and follow-up care. This study platform aims to identify germline genetic variants associated with acute and late complications of childhood cancer.
Methods The Genetic Risks for Childhood Cancer Complications Switzerland (GECCOS) study is a nationwide cohort study. It includes patients and survivors who were diagnosed with childhood cancers or Langerhans cell histiocytosis before age 21 years, were registered in the Swiss Childhood Cancer Registry (SCCR) since 1976 and have consented to the Pediatric Biobank for Research in Hematology and Oncology (BaHOP), Geneva, host of the Germline DNA Biobank Switzerland for Childhood Cancer and Blood Disorders (BISKIDS). BISKIDS is a national biobank for the collection of germline DNA in childhood cancer patients and survivors.
GECCOS uses demographic and clinical data from the SCCR and the associated Swiss Childhood Cancer Survivor Study (SCCSS), which contains health-related data of survivors. Phenotypic data consist of objective measurements, health conditions diagnosed by physicians, second primary neoplasms, self-reported and health-related information from participants. Germline genetic samples and sequencing data have been collected in BISKIDS. We will perform gene panel sequencing, whole-exome sequencing, or whole-genome sequencing depending on the research questions. We will perform association analyses to identify genetic variants associated with specified health conditions. We will use clustering and machine-learning techniques and assess multiple health conditions in different models.
Discussion GECCOS will serve as an overarching platform to enable genotype-phenotype association analyses on complications associated with childhood cancer and its treatments. Knowledge of germline genetic variants associated with childhood cancer-associated health conditions will help to further individualize cancer treatment and follow-up care, potentially resulting in improved efficacy and reduced side effects, for personalized cancer care.
Trial registration Clinicaltrials.gov: NCT04702321
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04702321
Funding Statement
This study is supported by the CANSEARCH Foundation for BISKIDS, the host biobank BaHOP, the research study GECCOS, and salary support to Nicolas Waespe. Further funding comes from the Swiss National Science Foundation (31BL30_185396), and Swiss Cancer Research (KFS-4722-02-2019, KLS/KFS-4825-01-2019). The funding bodies have no role in the design of the study and collection, analysis, and interpretation of data and in writing this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval and consent to participate The Geneva Cantonal Commission for Research Ethics has approved the GECCOS study (approval 2020-01723), and the BaHOP biobank (approval PB_2017-00533). The sponsor of the GECCOS study is the University Hospital Geneva, Rue Willy-Donze 6, 1211 Geneva 4, Switzerland; responsible person: Prof. Klara Posfay Barbe, e-mail: klara.posfaybarbe{at}hcuge.ch The current version of the GECCOS protocol when this manuscript was submitted: Version 1.0; May 28th, 2020. Changes in the protocol will be communicated to collaborators by the principal investigator and the main study team, if relevant, and amendments made on clinicaltrials.gov.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets that will be generated within GECCOS and/or analyzed during the study will not be publicly available due to concerns for anonymity of patients with childhood cancer being a rare disease. Datasets are available from the corresponding author on reasonable request for specific projects.
Abbreviations table
- ALL
- Acute lymphoblastic leukemia
- BaHOP
- Biobank for Hematology and Oncology in Pediatrics
- BISKIDS
- Germline DNA Biobank Switzerland for Childhood Cancer and Blood Disorders
- CNS
- Central nervous system
- CPS
- Cancer predisposition syndrome
- DNA
- Deoxyribonucleic acid
- EWAS
- Exome-wide association study
- GECCOS
- Genetic risks for childhood cancer complications Switzerland GWAS Genome-wide association study
- HSCT
- Hematopoietic stem cell transplantation
- IARC
- International Agency for Research on Cancer
- ICCC-3
- International Classification of Childhood Cancer, third edition ISPM Institute of Social and Preventive Medicine
- LCH
- Langerhans cell histiocytosis
- SCCR
- Swiss Childhood Cancer Registry
- SCCSS
- Swiss Childhood Cancer Survivors Study
- SPN
- Second primary neoplasm
- WHO
- World Health Organization
